TNFSF11 and osteoporosis: This study provides new mechanistic insights into how discontinuation of the anti-RANKL antibody causes an osteoclastic burst and disrupts normal bone metabolism, which has important implications for the clinical management of patients with osteoporosis in need of long-term treatment and diverse therapeutic options.